CTKB on Nasdaq

Cytek Biosciences, Inc.

American laboratory analytical instruments company based in Dover. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Pacific Biosciences, Quanterix (United States) or Harvard Bioscience, or pick any stock.

  • TickerCTKB on Nasdaq2
  • IndustryLaboratory Analytical Instruments2
  • HeadquartersDover, United States2
  • Incorporated inDE3
  • Business address47215 Lakeview Boulevard, Fremont, Ca 945383
  • Filer categoryAccelerated filer3
  • Legal formCorporation2
  • LEI549300K2J28BOC6FBO892
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o COGENCY GLOBAL INC., 850 NEW BURTON ROAD SUITE 201, 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 56281752

See how the biggest companies compare on our leaderboards

We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

51.8%Gross margin5
-20.0%Operating margin5
-33.0%Net margin5
0.5%Revenue growth, 20255
-19.5%Return on equity5
-$8.8MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 72% of the revenue Cytek Biosciences, Inc. broke down this way in fiscal 2025.

  1. Product$144.2M572%down 6% from 2024
  2. Service$57.3M528%up 21% from 2024
Products and services by year
Products and services202320242025
Product$156.7M$153.3M$144.2M
Service$36.3M$47.2M$57.3M

Regions

United States brought in 45% of the revenue Cytek Biosciences, Inc. broke down this way in fiscal 2025.

  1. United States$95.2M545%up 3% from 2024
  2. EMEA$55.9M526%down 10% from 2024
  3. Asia Pacific$41.1M519%up 15% from 2024
  4. China$20.5M510%
Regions by year
Regions202320242025
United States$102.1M$92.6M$95.2M
EMEA$53.2M$62.3M$55.9M
Asia Pacific$31.6M$35.8M$41.1M
China$20.5M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue48¢$97.0M
  • Research and development18¢$36.5M
  • Other costs16¢$31.3M
  • Income tax18¢$36.7M

Out of $201.5M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$201.5M in 2025+117% since 2020
0$100.0M$200.0M$300.0M2020: $92.8M$92.8M20202021: $128.0M$128.0M2021+38%2022: $164.0M$164.0M2022+28%2023: $193.0M$193.0M2023+18%2024: $200.5M$200.5M2024+4%2025: $201.5M$201.5M2025+1%
Gross profit6785$104.5M in 2025+102% since 2020
0$50.0M$100.0M$150.0M2020: $51.7M$51.7M20202021: $79.1M$79.1M2021+53%2022: $101.0M$101.0M2022+28%2023: $109.4M$109.4M2023+8%2024: $111.1M$111.1M2024+2%2025: $104.5M$104.5M2025−6%
Operating income6785-$40.4M in 2025
-$60.0M-$40.0M-$20.0M0$20.0M2020: $13.7M$13.7M20202021: $9.2M$9.2M2021−33%2022: -$1.8M-$1.8M20222023: -$27.8M-$27.8M2023+1444%2024: -$20.5M-$20.5M2024−26%2025: -$40.4M-$40.4M2025+97%
Net income6785-$66.5M in 2025
-$75.0M-$50.0M-$25.0M0$25.0M2020: $19.4M$19.4M20202021: $3.0M$3.0M2021−84%2022: $2.5M$2.5M2022−18%2023: -$12.1M-$12.1M20232024: -$6.0M-$6.0M2024−50%2025: -$66.5M-$66.5M2025+1005%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenue, net$201.5M$200.5M$193.0M
Total cost of sales$97.0M$89.3M$83.6M
Gross profit$104.5M$111.1M$109.4M
Research and development$36.5M$39.4M$44.2M
Sales and marketing$49.4M$49.1M$49.1M
General and administrative$58.9M$43.1M$44.0M
Total operating expenses$144.8M$131.6M$137.3M
Loss from operations-$40.4M-$20.5M-$27.8M
Interest income (expense), net (Notes 11, 12)-$474.0K$5.2M-$2.1M
Interest income$2.2M$5.1M$6.4M
Other income, net$8.8M$4.5M$7.8M
Total other income, net$10.5M$14.8M$12.1M
Loss before income taxes-$29.8M-$5.7M-$15.7M
Provision for (benefit from) income taxes$36.7M$320.0K-$3.6M
Less: net loss allocated to noncontrolling interests$0$0$0
Net loss attributable to common stockholders, basic-$66.5M-$6.0M-$12.1M
Net loss attributable to common stockholders, diluted-$66.5M-$6.0M-$12.1M
Net loss attributable to common stockholders per share, basic (in dollars per share)-$1-$0-$0
Net loss attributable to common stockholders per share, diluted (in dollars per share)-$1-$0-$0
Weighted-average shares used in calculating net loss per share, basic (in shares)127.7M shares130.6M shares135.3M shares
Weighted-average shares used in calculating net loss per share, diluted (in shares)127.7M shares130.6M shares135.3M shares
Net loss-$66.5M-$6.0M-$12.1M
Foreign currency translation adjustment, net of tax$2.2M$1.2M-$549.0K
Unrealized gain (loss) on marketable securities$58.0K$97.0K-$29.0K
Net comprehensive loss-$64.3M-$4.7M-$12.7M

Compare Cytek Biosciences, Inc. with another company

Leadership

Who has led Cytek Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Patrik Jeanmonod2021–2024
  2. William D. McCombe2024–now
2025
Board members and other officers (19)

Timeline

  1. Dec 15, 2014Founded Cytek Biosciences, Inc. is founded2

Filings

414 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 272 insider forms, 34 large holders, 44 other. The latest 20:

  1. Sep 29, 20268-K EDGAR
  2. Sep 2, 2026144 EDGAR
  3. Aug 24, 20268-K EDGAR
  4. Aug 20, 20264 EDGAR
  5. Aug 20, 20264 EDGAR
  6. Aug 20, 20264 EDGAR
  7. Aug 20, 20264 EDGAR
  8. Aug 20, 20264 EDGAR
  9. Aug 20, 20264 EDGAR
  10. Aug 12, 20264 EDGAR
  11. Aug 6, 2026SCHEDULE 13G/A EDGAR
  12. Aug 5, 202610-Q EDGAR
  13. Aug 5, 20268-K EDGAR
  14. Aug 4, 2026SCHEDULE 13G EDGAR
  15. Jul 15, 20268-K EDGAR
  16. Jul 8, 2026SCHEDULE 13G/A EDGAR
  17. Jun 30, 20263 EDGAR
  18. Jun 25, 20268-K EDGAR
  19. Jun 16, 20264 EDGAR
  20. Jun 16, 20268-K EDGAR

The 414 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

92 open-market trades by officers, directors and large owners since October 2021: 21 buys and 71 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2025McCombe William D.Chief Financial OfficerBuy35,000$2.78$97.3KForm 4
Apr 19, 2024Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$5.87$117.4KForm 4
Apr 9, 2024Yan MingCHIEF TECHNOLOGY OFFICERSale1,900$7.00$13.3KForm 4
Mar 19, 2024Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$6.71$134.2KForm 4
Mar 18, 2024Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$6.77$135.4KForm 4
Dec 26, 2023Jeanmonod PatrikCHIEF FINANCIAL OFFICERSale3,000$9.50$28.5KForm 4
Dec 19, 2023Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$9.43$188.6KForm 4
Nov 24, 2023Jeanmonod PatrikCHIEF FINANCIAL OFFICERSale3,000$6.94$20.8KForm 4
Nov 20, 2023Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$6.03$120.6KForm 4
Nov 7, 2023Jiang WenbinPRESIDENT AND CEOSale20,000$4.34$86.8KForm 4
Oct 24, 2023Jeanmonod PatrikCHIEF FINANCIAL OFFICERSale3,000$4.68$14.0KForm 4
Oct 19, 2023Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$4.80$96.0KForm 4
Oct 9, 2023Jiang WenbinPRESIDENT AND CEOSale20,000$5.33$106.6KForm 4
Sep 25, 2023Jeanmonod PatrikCHIEF FINANCIAL OFFICERSale3,000$6.38$19.1KForm 4
Sep 19, 2023Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$6.49$129.8KForm 4
Sep 7, 2023Jiang WenbinPRESIDENT AND CEOSale20,000$6.83$136.6KForm 4
Aug 24, 2023Jeanmonod PatrikCHIEF FINANCIAL OFFICERSale3,000$7.69$23.1KForm 4
Aug 21, 2023Yan MingCHIEF TECHNOLOGY OFFICERSale20,000$8.07$161.4KForm 4
Aug 7, 2023Jiang WenbinPRESIDENT AND CEOSale20,000$9.04$180.8KForm 4
Jul 24, 2023Jeanmonod PatrikCHIEF FINANCIAL OFFICERSale3,000$9.17$27.5KForm 4

All 92 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.9,578,643$42.4M0.0%−7,428,626
Millennium Management LLC9,338,010$41.4M0.0%+3,046,212
Boston Partners7,660,943$33.9M0.0%+1,858,170
Hhlr Advisors, Ltd.6,657,030$29.5M3.5%No change
Topline Capital Management, LLC6,283,450$27.8M7.2%−781,031
Vanguard Capital Management LLC4,939,597$21.9M0.0%+176,693
Geode Capital Management, LLC3,059,573$13.6M0.0%+225,618
Dimensional Fund Advisors LP2,616,257$11.6M0.0%−47,072
State Street Corp2,566,121$11.4M0.0%−1,557,627
Goldman Sachs Group Inc2,167,515$9.6M0.0%−177,220
Royce & Associates LP2,081,579$9.2M0.1%+439,211
Russell Investments Group, Ltd.1,511,315$6.7M0.0%+151,415
Bank Of America Corp /de/1,315,332$5.8M0.0%+306,278
Vanguard Portfolio Management LLC1,141,592$5.1M0.0%−1,170,266
Charles Schwab Investment Management Inc1,073,253$4.8M0.0%−31,348
Northern Trust Corp1,003,294$4.4M0.0%−1,899
Arrowstreet Capital, Limited Partnership973,833$4.3M0.0%+653,924
Jane Street Group, LLC906,162$4.0M0.0%New
Tudor Investment Corp Et Al837,913$3.7M0.0%+517,198
Aqr Capital Management LLC813,971$3.6M0.0%−98,371
Vanguard Fiduciary Trust Co740,662$3.3M0.0%+23,651
Citadel Advisors LLC721,470$3.2M0.0%+250,078
Morgan Stanley701,792$3.1M0.0%−1,017,083
Qube Research & Technologies Ltd689,821$3.1M0.0%New
Susquehanna International Group, Llp681,705$3.0M0.0%+625,695

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42